2-[(3S,4R)-3-[(4-chlorophenyl)methoxy]-5-[(2S,4S,5R)-4-hydroxy-5-(hydroxymethyl)-2-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]-4-(hydroxymethyl)-2-(2-sulfoethyl)oxolan-2-yl]ethanesulfonic acid

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 2-[(3S,4R)-3-[(4-chlorophenyl)methoxy]-5-[(2S,4S,5R)-4-hydroxy-5-(hydroxymethyl)-2-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]-4-(hydroxymethyl)-2-(2-sulfoethyl)oxolan-2-yl]ethanesulfonic acid
• 化学式: C₂₆H₃₅ClN₂O₁₄S₂
• 分子量: 699.1
• InChiKey: GYSMMKDQJQAWFP-WSCHTBGVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  45
• 可旋转键数：
  13
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  263
• 氢给体数：
  6
• 氢受体数：
  14

文献信息

• BRIDGED BICYCLIC NUCLEOSIDES
  申请人：MIRAGEN THERAPEUTICS, INC.

  公开号：US20160010090A1

  公开（公告）日：2016-01-14

  The present invention relates to 2′-C-Bridged Bicyclic Nucleosides and Nucleotides, and oligonucleotides comprising at least one 2′-C-Bridged Bicyclic Nucleotides. The present invention further provides pharmaceutical compositions comprising the nucleosides, nucleotides, and oligonucleotides, as well as their respective methods of use and synthesis.

  本发明涉及2'-C-桥接双环核苷和核苷酸，以及包含至少一个2'-C-桥接双环核苷的寡核苷酸。本发明还提供包含这些核苷、核苷酸和寡核苷酸的药物组合物，以及它们各自的使用和合成方法。
• Bridged bicyclic nucleosides
  申请人：MIRAGEN THERAPEUTICS, INC.

  公开号：US10011833B2

  公开（公告）日：2018-07-03

  The present invention relates to 2′-C-Bridged Bicyclic Nucleosides and Nucleotides, and oligonucleotides comprising at least one 2′-C-Bridged Bicyclic Nucleotides. The present invention further provides pharmaceutical compositions comprising the nucleosides, nucleotides, and oligonucleotides, as well as their respective methods of use and synthesis.

  本发明涉及2′-C-桥双环核苷和核苷酸，以及包含至少一种2′-C-桥双环核苷酸的寡核苷酸。本发明进一步提供了包含核苷酸、核苷酸和寡核苷酸的药物组合物，以及它们各自的使用和合成方法。
• SYNTHESIS OF BICYCLIC NUCLEOSIDES
  申请人：MIRAGEN THERAPEUTICS, INC.

  公开号：US20170073368A1

  公开（公告）日：2017-03-16

  The present disclosure provides methods for synthesizing modified nucleosides, nucleotides, and oligonucleotides comprising at least one 2′-C-Bridged Bicyclic Nucleotide, and to intermediates used in the process.
• [EN] BRIDGED BICYCLIC NUCLEOSIDES<br/>[FR] NUCLÉOSIDES BICYCLIQUES PONTÉS
  申请人：MIRAGEN THERAPEUTICS INC

  公开号：WO2014145356A1

  公开（公告）日：2014-09-18

  The present invention relates to 2'-C-Bridged Bicyclic Nucleosides and Nucleotides, and oligonucleotides comprising at least one 2'-C-Bridged Bicyclic Nucleotides. The present invention further provides pharmaceutical compositions comprising the nucleosides, nucleotides, and oligonucleotides, as well as their respective methods of use and synthesis.